SinoVeda signs commercialization agreement with Exzell Pharma for Effecti-Cal

SinoVeda Canada has signed an exclusive license agreement with Exzell Pharma to commercialize Effecti-Cal in Canada, the US, Australia and New Zealand.

The agreement includes upfront and milestone payments, as well as royalties on sales.

Health Canada has approved Effecti-Cal as a Natural Health Product to support the development and maintenance of healthy bones and teeth.

The product is a source of highly soluble and absorbable calcium, magnesium, and zinc that can be taken with or without food.

SinoVeda Canada president, chief scientific officer and co-founder Dr Yun Tam said: "We are extremely pleased with this first commercial deal for Effecti-Cal.

"The bone health marketplace is sorely lacking in products that have meaningful scientifically validated benefits, and we are pleased to be working with Exzell Pharma to make Effecti-Cal available to consumers in these first markets."

According to the company, Effecti-Cal is well tolerated and has fewer side effects compared to other calcium supplements, which cause gastrointestinal side effects such as constipation, gas, bloating, and abdominal pain.

Effecti-Cal is a new form of multi-element calcium product designed to maintain bone health and reduce the risk of developing osteoporosis, a medical condition characterized by low bone density and deterioration of bone tissue.

Compared to existing calcium products, Effecti-Cal is designed to be more soluble in the intestine as well as provide more usable calcium per dose.